Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 0.48 |
| ▸ | GRK2 | P25098 | 17/20 | 0.48 |
| ▸ | GRK3 | P35626 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 7/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | GRK5 | P34947 | 1/20 | 0.39 |
| ▸ | GRK7 | Q8WTQ7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4790463 | 0.82 | ROCK2 (0.58) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL14289631 | 0.77 | ROCK2 (0.51) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL5116803 | 0.77 | ROCK2 (0.50) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL7433171 | 0.75 | MMP13 (0.48) | CACNA1GCACNA1BCACNA1C | |
| SCHEMBL5108758 | 0.74 | ROCK2 (0.56) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL5109256 | 0.73 | ROCK2 (0.52) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL14736600 | 0.71 | LMNA (0.50) | ROCK2GRK2LMNA | |
| SCHEMBL14736246 | 0.70 | PRKAB2 (0.48) | LMNA | |
| SCHEMBL4789113 | 0.69 | ROCK2 (0.55) | ROCK2GRK2GRK3PRKCAGRK5 | |
| SCHEMBL18186367 | 0.69 | ALDH1A1 (0.39) | CACNA1GCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | ROCK2 2/4885GRK2 254/4885GRK3 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.